CSCI — COSCIENS Biopharma Share Price
Last trade - 00:00- CA$16.11m
- CA$0.21m
- $9.59m
- 21
- 46
- 66
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.15 | ||
| Price to Tang. Book | 1.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.29 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.35% | ||
| Return on Equity | -151.97% | ||
| Operating Margin | -222.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.65 | 5.26 | 5.64 | 7.14 | 9.59 | n/a | n/a | 78.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Directors
- Carolyn Egbert NEC
- Klaus Paulini PRE
- Giuliano La Fratta CFO
- Eckhard Gunther SVP
- Nicola Ammer SVP
- Guenther Grau VFN
- Matthias Gerlach VPR
- Dennis Turpin DRC
- Pierre-Yves Desbiens IND
- Peter Edwards IND (57)
- Gilles Gagnon IND
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 12th, 1990
- Public Since
- December 19th, 1995
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 3,146,492
- Address
- C/O Norton Rose Fulbright Canada Llp, TORONTO, M5K 1E7
- Web
- https://www.cosciensbio.com/
- Phone
- +1 4186528525
- Auditors
- Deloitte LLP
Upcoming Events for CSCI
Similar to CSCI
Appili Therapeutics
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
Eupraxia Pharmaceuticals
Toronto Stock Exchange
FAQ
As of Today at 20:03 UTC, shares in COSCIENS Biopharma are trading at CA$5.12. This share price information is delayed by 15 minutes.
Shares in COSCIENS Biopharma last closed at CA$5.12 and the price had moved by -37.56% over the past 365 days. In terms of relative price strength the COSCIENS Biopharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -48.64% over the past year.
The overall consensus recommendation for COSCIENS Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCOSCIENS Biopharma does not currently pay a dividend.
COSCIENS Biopharma does not currently pay a dividend.
COSCIENS Biopharma does not currently pay a dividend.
To buy shares in COSCIENS Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$5.12, shares in COSCIENS Biopharma had a market capitalisation of CA$16.11m.
Here are the trading details for COSCIENS Biopharma:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: CSCI
Based on an overall assessment of its quality, value and momentum COSCIENS Biopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like COSCIENS Biopharma. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +25.87%.
As of the last closing price of CA$5.12, shares in COSCIENS Biopharma were trading +13.25% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The COSCIENS Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$5.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
COSCIENS Biopharma's management team is headed by:
- Carolyn Egbert - NEC
- Klaus Paulini - PRE
- Giuliano La Fratta - CFO
- Eckhard Gunther - SVP
- Nicola Ammer - SVP
- Guenther Grau - VFN
- Matthias Gerlach - VPR
- Dennis Turpin - DRC
- Pierre-Yves Desbiens - IND
- Peter Edwards - IND
- Gilles Gagnon - IND